- Article
Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
- Doan T. M. Ngo,
- Trent Williams,
- Sophie Horder,
- Leonard Kritharides,
- Janette Vardy,
- Hiren Mandaliya,
- Ina I. C. Nordman,
- James Lynam,
- Tony Bonaventura and
- Aaron L. Sverdlov
Background: Bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody commonly used for the treatment of various cancers, is often associated with adverse cardiovascular effects such as hypertension, cardiac and cerebral ischemia,...

